Anti-Coagulants - Malaysia | Statista Market Forecast

The Anti-Coagulants market in Malaysia is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is estimated to reach US$45.26m in 2024.
Furthermore, a steady annual growth rate of 8.05% is anticipated from 2024 to 2029, leading to a market volume of US$66.66m by the end of 2029.
In terms of global comparison, it is worth noting that United States is expected to generate the highest revenue in the Anti-Coagulants market, with an estimated value of US$16.74bn in 2024.
The demand for anti-coagulants in Malaysia is growing steadily due to an aging population and increasing prevalence of cardiovascular diseases.

Definition:
The Anti-Coagulants market covers drugs that prevent blood from clotting, i.e., that prolong the clotting time. Anti-coagulants are certain types of antithrombotics, which are often also called blood thinners. Neither thrombolytic drugs, which dissolve clots after they have formed, nor other anti-thrombotics, such as antiplatetelet drugs, are covered in this market.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol Myers Squibb, Bayer, Sanofi, Johnson & Johnson

Blood clotting inhibitors

Anti-fibrinolytics
Anti-hypertensives
Other hematology drugs
Other anti-thrombotic agents, such as platelet aggregation inhibitors
Thrombolytic drugs

The demand for Anti-Coagulants in Malaysia has been steadily increasing over the past few years.

Customer preferences: Patients in Malaysia are increasingly opting for Anti-Coagulants due to the rising incidence of cardiovascular diseases and stroke. The aging population and sedentary lifestyles have also contributed to the growing demand for Anti-Coagulants.

Trends in the market: The Anti-Coagulants market in Malaysia is witnessing a shift towards newer oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, and apixaban. These NOACs have several advantages over traditional anticoagulants such as warfarin, including fewer drug interactions, no need for regular monitoring, and a lower risk of bleeding. This trend towards NOACs is expected to continue in the coming years.

Local special circumstances: One of the unique challenges in the Malaysian market is the lack of awareness about the importance of anticoagulation therapy among patients and healthcare providers. This has led to underutilization of Anti-Coagulants in the country. However, efforts are being made to increase awareness and improve access to Anti-Coagulants in Malaysia.

Underlying macroeconomic factors: The Malaysian government has been investing heavily in the healthcare sector, which has led to an increase in the availability and affordability of Anti-Coagulants in the country. Additionally, the growing middle class and increasing healthcare expenditure have also contributed to the growth of the Anti-Coagulants market in Malaysia.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.